Expanding its pipeline of gene therapies for neurological disorders, Neurocrine Biosciences has partnered up with Voyager Therapeutics to develop and commercialise four of Voyager’s gene therapy programmes – VY-AADC for Parkinson’s disease (PD) and VY-FXN01 for Friedreich’s ataxia (FA) as well as rights to two programmes to be determined. The deal, worth potentially US$1.9 B, comes after the US FDA announced that the current Phase II trial for VY-AADC was insufficient for filing leaving Voyager desperately seeking funds to support full Phase II and Phase III trials.